Kiniksa Pharmaceuticals
KNSA
132 hedge funds and large institutions have $340M invested in Kiniksa Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 57 increasing their positions, 32 reducing their positions, and 16 closing their positions.
124% more call options, than puts
Call options by funds: $4.83M | Put options by funds: $2.16M
78% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 32
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
6% more funds holding
Funds holding: 125 → 132 (+7)
4.77% more ownership
Funds ownership: 86.62% → 91.39% (+4.8%)
24% less capital invested
Capital invested by funds: $446M → $340M (-$107M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.9M |
| 2 |
Morgan Stanley
New York
|
+$9.49M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$8.68M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.05M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$21.2M |
| 2 |
Goldman Sachs
New York
|
-$7.83M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$3.66M |
| 4 |
LPC
Lion Point Capital
New York
|
-$3.07M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.02M |
KNSA Hedge Fund Activity: Q1 2023 in Review
132 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2023, worth a combined $340M — down 24% from $446M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KNSA positions and 16 closed out — a net gain of 7 holders — while 57 added to existing stakes and 32 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $15.9M. The largest seller was HHLR Advisors, cutting an estimated $21.2M.
- 132 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2023, up from 125 in Q4 2022.
- Funds reported $340M of Kiniksa Pharmaceuticals stock for Q1 2023, down 24% quarter-over-quarter.
- 23 funds opened new Kiniksa Pharmaceuticals positions in Q1 2023 and 16 closed out, a net change of +7 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2023 was Rubric Capital Management (New York), an estimated $15.9M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2023 was HHLR Advisors, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2023.